The short answer
Eli Lilly reported TRIUMPH-2 and TRIUMPH-3 in July 2026. Both met their primary endpoints. TRIUMPH-3, in adults with severe obesity and established cardiovascular disease, reported mean weight reduction up to 22.6% at 80 weeks. Together they extend the programme beyond uncomplicated obesity into its two most clinically significant comorbid populations.
Key facts
- Reported
- July 2026
- TRIUMPH-2 population
- Obesity with type 2 diabetes
- TRIUMPH-3 population
- Severe obesity with established CVD
- TRIUMPH-3 result
- Up to 22.6% mean reduction at 80 weeks
- Primary endpoints
- Met in both trials
- Programme enrolment
- More than 5,800 participants
- Planned FDA filing
- Q1 2027
Why these two trials matter more than the headline number
TRIUMPH-1 answered how much weight reduction is achievable in a relatively uncomplicated obesity population. That is the easier question. TRIUMPH-2 and TRIUMPH-3 ask whether the same compound performs in people who actually carry the conditions that make obesity dangerous. Type 2 diabetes in one case, established cardiovascular disease in the other. Regulators and payers weight these populations heavily, because they are where the clinical benefit has to be demonstrated.
TRIUMPH-3 and the cardiovascular population
In adults with severe obesity and established cardiovascular disease, mean reduction reached up to 22.6% at 80 weeks. The figure is lower than TRIUMPH-1's 28.3%, which is expected: this is an older, sicker population with more concomitant medication and different tolerability constraints. That it met its primary endpoint in this group is the substantive finding.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
TRIUMPH-2 and glycaemic control
The type 2 diabetes study reported improvements in both body weight and A1C. Weight reduction in diabetic populations is typically attenuated compared with non-diabetic ones across the entire incretin class, so comparisons should be made within population rather than against the TRIUMPH-1 headline.
What is still outstanding
Seven further Phase 3 readouts were expected across 2026, including studies of maintenance dosing strategies. That is, what happens when the dose is reduced or stopped after the initial reduction phase. Weight regain after discontinuation is the open question across the whole incretin class, and maintenance data are what the field is actually waiting on.
Regulatory position
Positive pivotal data do not confer authorisation. Retatrutide remains investigational in every jurisdiction, including the UK. Lilly has indicated an intended Biologics License Application to the FDA in the first quarter of 2027; MHRA and EMA timelines have not been stated publicly.
Frequently asked questions
Why is the TRIUMPH-3 number lower than TRIUMPH-1?
Different populations. TRIUMPH-3 enrolled adults with severe obesity and established cardiovascular disease, in whom attenuated response is the expected pattern across the class.
Has retatrutide been submitted to the MHRA?
No public filing has been announced with the MHRA. The stated plan is an FDA submission in Q1 2027.
What are the maintenance trials looking at?
Whether reduction is sustained when dosing is lowered or stopped. This is the main unresolved question for incretins generally, not only for retatrutide.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- RefRetatrutide successful in two additional Phase 3 obesity trials. Eli Lillyinvestor.lilly.com
- RefLilly's retatrutide positive topline Phase III results. PharmExecpharmexec.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- Where the MHRA Draws the Line on Research PeptidesUK law regulates claims and intended use, not the compound. What makes a product an unlicensed medicine, and how the MHRA has enforced that line in 2026.
- Counterfeit GLP-1 Products: The 2026 UK PictureMHRA seizures of counterfeit GLP-1 pens, a 265% rise in US poison-centre exposures, and why certificate-of-analysis verification is the only practical defence.
- Orforglipron in the UK: Access, Cost and the NHS QuestionFoundayo is available in the UK on private prescription only, reported at roughly £99-£179 a month. NHS funding awaits NICE guidance expected 18 November 2026.
- Orforglipron: Reported Side Effects and TolerabilityNausea, constipation, diarrhoea, vomiting, dyspepsia and abdominal pain are most commonly reported. Why the profile is a GLP-1 class effect, not a surprise.
- How NICE Decides Whether the NHS Funds a MedicineLicensing and funding are separate decisions. How NICE appraisal works, why obesity medicines are difficult cases, and what is expected on 18 November 2026.